Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To assess the effectiveness and safety of intravitreal ranibizumab compared with bevacizumab forthe treatment of macular edema associated with branch retinal vein occlusion (BRVO). Methods: This was a retrospective study of 80 eyes with macular edema associated with BRVO. Patientsreceived either 0.5 mg of ranibizumab (n = 24) or 1.25 mg of bevacizumab (n = 56) intravitreally. Both groupsreceived three initial monthly injections followed by as-needed injections. The best-corrected visual acuity,central subfield thickness, mean number of injections, and retreatment rate were evaluated monthly for 6months after the initial injection. Results: The best-corrected visual acuity significantly improved from logarithm of the minimal angle of resolution(logMAR) 0.55 ± 0.26 at baseline to 0.24 ± 0.26 at 6 months in the ranibizumab group (p < 0.001) andfrom logMAR 0.58 ± 0.21 at baseline to 0.29 ± 0.25 at 6 months in the bevacizumab group (p < 0.001), whichis not a statistically significant difference (p = 0.770). The mean reduction in central subfield thickness at 6months was 236 ± 164 μm in the ranibizumab group (p < 0.001) and 219 ± 161 μm in the bevacizumab group (p< 0.001), which is not also a statistically significant difference (p = 0.698). The mean numbers of ranibizumaband bevacizumab injections were 3.25 ± 0.53 and 3.30 ± 0.53, respectively (p = 0.602). In addition, after thethree initial monthly injections, the retreatment rates for ranibizumab and bevacizumab injections were 20.8%and 26.7%, respectively (p = 0.573). Conclusions: Both ranibizumab and bevacizumab were effective for the treatment of BRVO and producedsimilar visual and anatomic outcomes. In addition, the mean number of injections and the retreatment rateswere not significantly different between the groups.
Abstract
Purpose: To assess the effectiveness and safety of intravitreal ranibizumab compared with bevacizumab forthe treatment of macular edema associated with branch retinal vein occlusion (BRVO). Methods: This was a retrospective study of 80 eyes with macular edema associated with BRVO. Patientsreceived either 0.5 mg of ranibizumab (n = 24) or 1.25 mg of bevacizumab (n = 56) intravitreally. Both groupsreceived three initial monthly injections followed by as-needed injections. The best-corrected visual acuity,central subfield thickness, mean number of injections, and retreatment rate were evaluated monthly for 6months after the initial injection. Results: The best-corrected visual acuity significantly improved from logarithm of the minimal angle of resolution(logMAR) 0.55 ± 0.26 at baseline to 0.24 ± 0.26 at 6 months in the ranibizumab group (p < 0.001) andfrom logMAR 0.58 ± 0.21 at baseline to 0.29 ± 0.25 at 6 months in the bevacizumab group (p < 0.001), whichis not a statistically significant difference (p = 0.770). The mean reduction in central subfield thickness at 6months was 236 ± 164 μm in the ranibizumab group (p < 0.001) and 219 ± 161 μm in the bevacizumab group (p< 0.001), which is not also a statistically significant difference (p = 0.698). The mean numbers of ranibizumaband bevacizumab injections were 3.25 ± 0.53 and 3.30 ± 0.53, respectively (p = 0.602). In addition, after thethree initial monthly injections, the retreatment rates for ranibizumab and bevacizumab injections were 20.8%and 26.7%, respectively (p = 0.573). Conclusions: Both ranibizumab and bevacizumab were effective for the treatment of BRVO and producedsimilar visual and anatomic outcomes. In addition, the mean number of injections and the retreatment rateswere not significantly different between the groups.
참고문헌 (24)
- Klein R, "The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study", Arch Ophthalmol, 126, pp.513~518 (2008)
- Rogers S, "The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia", Ophthalmology, 117, pp.313~319.e1 (2010)
- Christoffersen NL, "Pathophysiology and hemodynamics of branch retinal vein occlusion", Ophthalmology, 106, pp.2054~2062 (1999)
- Rehak J, "Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities", Curr Eye Res, 33, pp.111~131 (2008)
- Antonetti DA, "Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells: Penn State Retina Research Group", Diabetes, 47, pp.1953~1959 (1998)
- Campochiaro PA, "Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator", Mol Ther, 16, pp.791~799 (2008)
- Noma H, "Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion", Eye (Lond), 22, pp.42~48 (2008)
- Campochiaro PA, "Ranibizumab for macular edema following branch retinal vein occlusion:six-month primary end point results of a phase III study", Ophthalmology, 117, pp.1102~1112.e1 (2010)
- Yilmaz T, "Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review", Graefes Arch Clin Exp Ophthalmol, 250, pp.787~793 (2012)
- Ehlers JP, "Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion", Retina, 31, pp.1856~1862 (2011)
- Narayanan R, "A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion:MARVEL report no. 1", Br J Ophthalmol, 99, pp.954~959 (2015)
- "Argon laser photocoagulation for macular edema in branch vein occlusion: the Branch Vein Occlusion Study Group", Am J Ophthalmol, 98, pp.271~282 (1984)
- Scott IU, "A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6", Arch Ophthalmol, 127, pp.1115~1128 (2009)
- Haller JA, "Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion", Ophthalmology, 117, pp.1134.e3~1146.e3 (2010)
- Kim M, "Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion", Ophthalmologica, 227, pp.132~138 (2012)
- Siegel RA, "Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting", Curr Eye Res, 37, pp.823~829 (2012)
- Bakri SJ, "Pharmacokinetics of intravitreal ranibizumab (Lucentis)", Ophthalmology, 114, pp.2179~2182 (2007)
- Bakri SJ, "Pharmacokinetics of intravitreal bevacizumab (Avastin)", Ophthalmology, 114, pp.855~859 (2007)
- Mordenti J, "Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration", Toxicol Pathol, 27, pp.536~544 (1999)
- Terasaki H, "Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro", Retina, 35, pp.1007~1015 (2015)
- Papadopoulos N, "Binding and neutralization of vascular endothelial growth factor (VEGF)and related ligands by VEGF trap, ranibizumab and bevacizumab", Angiogenesis, 15, pp.171~185 (2012)
- Yu L, "Comparing protein VEGF inhibitors:in vitro biological studies", Biochem Biophys Res Commun, 408, pp.276~281 (2011)
- Berg K, "Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol", Ophthalmology, 122, pp.146~152 (2015)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)